Food intake and body weight were measured every 2 days throughout the experimental period
According to our model, long-term CR may confer increased tumorigenic risks if there are durable and sustained increases in stem mutations and abnormal proliferation, DNA damage, epigenetic modification, and cell numbers that can undergo mutagenesis
Winners will be biotechs and products that deliver: Systemic metabolic platforms Therapies combining fat loss with muscle preservation Long-term maintenance and relapse-prevention solutions Adherence, formulation, and delivery innovations Losers will be biotechs or products characterized by: Mono-organ, late-stage interventions Products without meaningful weight or metabolic impact Incremental add-ons justified by biomarker shifts alone Startups at Strategic Risk in the Post-GLP-1++ Era Retatrutide does not merely compete with other drugs it raises the minimum threshold of relevance
The pediatric indication requires dedicated clinical trials demonstrating safety and efficacy in that age group, which Wegovy has, and Ozempic does not, says Omodamola Aje, MD , a board-certified endocrinologist
